JW Holdings has commenced the full-scale export of “WINUF Central 736-1085 ml,” a three-chamber comprehensive nutritional fluid product, to Asia Pharma LLC in Mongolia, as announced on Nov. 28.
JW Holdings, overseeing JW Group’s global operations, had previously secured an exclusive supply contract for WINUF in the Mongolian market with Asia Pharma in December 2021. Founded in 2002, Asia Pharma, a top pharmaceutical company, has a 21-year history of importing and distributing a wide range of pharmaceuticals and medical devices, including comprehensive nutritional fluids. Asia Pharma received product approval for WINUF from the Mongolian Ministry of Health in December last year and has started its official sales in the country this month.
Developed by JW Life Science, WINUF is an innovative comprehensive nutritional fluid that allows for easy mixing of various nutrients, including four types of lipids, amino acids, and glucose, within a single container divided into three chambers. Notable for its high concentration of omega-3 and omega-6 fatty acids, WINUF enhances patient immunity and recovery more effectively than traditional comprehensive nutritional fluids.
Domestically, JW Pharmaceutical manages the sales of WINUF, holding the leading position in South Korea’s comprehensive nutritional fluid market since its launch in 2013. This marks JW Holdings’ first venture in exporting WINUF to the Asian market, with expectations for expanding its exports to other Asian countries following the Mongolian venture.